Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity

Table 1 Effect of DPPC from different suppliers on GLA-AF physicochemical stability

DPPC supplier		Particle size (Z-ave, nm)		Pdl		Measured GLA concentration (μg/ml) [250 ± 50 μg/ml target]
DPPC supplier		DM	6 mo	DM	6 mo	DM	6 mo
NOF	Lot 1	85 ± 2	87 ± 3	0.27 ± 0.01	0.27 ± 0.01	222 ± 6	200 ± 3
NOF	Lot 2	78 ± 1	81 ± 2	0.31 ± 0.03	0.33 ± 0.04	206 ± 2	166 ± 2
Corden	Lot 1	88 ± 3	89 ± 2	0.28 ± 0.03	0.26 ± 0.01	209 ± 10	179 ± 5
Corden	Lot 2	102 ± 1	106 ± 2	0.24 ± 0.01	0.25 ± 0.01	206 ± 3	171 ± 11
Lipoid	Lot 1	101 ± 2	100 ± 2	0.27 ± 0.01	0.25 ± 0.01	230 ± 3	210 ± 3
Lipoid	Lot 2	86 ± 1	88 ± 2	0.27 ± 0.01	0.27 ± 0.03	212 ± 4	197 ± 2
Avanti	Lot 1	87 ± 1	85 ± 1	0.22 ± 0.01	0.21 ± 0.01	261 ± 4	231 ± 2
Avanti	Lot 2	93 ± 1	93 ± 1	0.26 ± 0.01	0.25 ± 0.01	223 ± 2	234 ± 2

ISSN: 1477-3155